This report describes an observed temporal association in a patient with psoriasis who was treated with the interleukin-17A inhibitor secukinumab for four years and subsequently developed metastatic medullary thyroid cancer. This evidence concerns the gene IL17A and medullary thyroid gland carcinoma.